Aaron Ajeti

Aaron Ajeti


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Maranda CantrellMaranda Cantrell
Maranda Cantrell
ASAlejandro Soto-Avellaneda
Alejandro Soto-Avellaneda
JWJackson D. Wall
Jackson D. Wall
AAAaron Ajeti
Aaron Ajeti
BMBrad E. Morrison
Brad E. Morrison
Owen M. McdougalOwen M. Mcdougal
Owen M. Mcdougal
Drug development is a complicated, slow and expensive process with high failure rates. One strategy to mitigate these factors is to recycle existing drugs with viable safety profiles and have gained Food and Drug Administration approval following extensive clinical trials. Cardiovascular and neurodegenerative diseases are difficult to treat, and there exist few effective therapeutics, necessitating the development of new, more efficacious drugs. Recent scientific studies have led to a mechanistic understanding of heart and brain disease progression, which has led researchers to assess myriad drugs for their potential as pharmacological treatments for these ailments. The focus of this review is to survey strategies for the selection of drug repurposing candidates and provide representative case studies where drug repurposing strategies were used to discover therapeutics for cardiovascular and neurodegenerative diseases, with a focus on anti-inflammatory processes where new drug alternatives are needed.